Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT06628336
Recruiting Observational

Post-Market Observational Study of the HARMONY® Evolution Implants and Instruments

NCT06628336 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2023-10-11
Last updated
2024-10-04

Condition(s) studied

Total Hip Replacement

Investigational drug(s) / intervention(s)

HARMONY EVOLUTION

HARMONY EVOLUTION: It is planned to include consecutive eligible subjects which will be treated with the HARMONY EVOLUTION devices.

Study summary

The purpose of this study is to evaluate the safety and performance of the HARMONY® Evolution implants in a series of operated subjects treated in THR.

The objective is to demonstrate that the evaluated implants are compliant with the state of the art and the performance (PMA score \> 15 points) \& safety claims (The expected acceptable revision rate (state of the art with a confidence interval of 95%) is 3% at 3 years, 5% at 5 years, 7% at 7 years and 10% at 10 years).

The endpoint of this study is to validate the expected performance of the HARMONY® Evolution implants with the PMA score at 10 years and to validate the safety claim with the expected acceptable revision rate at 10 years.

Eligibility

Sex
ALL
Min age
18 Years
Max age
99 Years
Healthy volunteers
No
Inclusion Criteria: * Subjects of 18 years of age and older * Each subject who is willing to give informed consent * Clinically indicated for a Total Hip Replacement * Women of childbearing age who are not pregnant and do not expect to become pregnant within 12 months. A pregnancy test should be performed for women of childbearing age * Geographically stable and willing to return to the implanting site for all follow-up visits Exclusion Criteria: * Acute or chronic, local or systemic infection * Muscular, neurological, psychological or vascular deficits * Poor bone density and quality likely to affect implant stability (severe osteoporosis) * Any concomitant condition likely to affect implant integration or function * Allergy or hypersensitivity to any of the materials used Specific: • The HARMONY® Evolution Standard stem size 8 shall not be implanted in subjects weighing more than 70 kg.

Primary outcome measure(s)

Trial sites (5)

FacilityCityRegionStatus
Polyclinique de Franche-Comté Besançon France Recruiting
Clinique Belledonne Grenoble France Recruiting
Clinique Juge Marseille France Recruiting
Clinique Arago Paris France Recruiting
Médipôle Garonne Toulouse France Recruiting

More Symbios Orthopedie SA trials in France

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06628336 on ClinicalTrials.gov ↗ ← All trials in France